News
Stay up to date on the latest crypto trends with our expert, in-depth coverage.
1Bitget UEX Daily | Israel-Lebanon Talks Boost Ceasefire Expectations; S&P 500 and Nasdaq Seven Consecutive Gains; Intel-Google Collaboration Hits New Stock High (April 10, 2026)2Bitcoin moved back above the $69.4K Traders' Lower Realized Price after ceasefire headlines, signaling a potential trend shift if bulls defend the level.3Asia-Pacific Markets Surge Following Iran Ceasefire – Yet the Momentum Is Fueled by Behavioral Biases Rather Than Core Fundamentals
LPTJPY’s 31% Spike Ends in Sharp Rejection at 456
101 finance·2026/04/10 15:54
Digital Asset Embrace Depends on Options as Oversight and Custody Progress
101 finance·2026/04/10 15:48
NVDA Climbs Toward $190—But Volume Tells a Different Story
101 finance·2026/04/10 15:48
Seabridge Gold Faces Permit Delay as Legal Win Offers Little Relief to Project Timeline Risk
101 finance·2026/04/10 15:48
XNDU Soars 12% on Thin Volume — Is This a Hollow Rally?
101 finance·2026/04/10 15:45
KXIN Rallies 15% on Weak Volume, Raising Bull Trap Fears
101 finance·2026/04/10 15:45
Is an Increase in Resale Speed Indicating Advancement in OPEN's Model Overhaul?
101 finance·2026/04/10 15:45
MTVA’s Rally Hits $1.35 Pivot—Will It Hold or Fade?
101 finance·2026/04/10 15:42
BitTensor AI Token Plunges as Top Builder Departs Over Decentralization Doubts
Decrypt·2026/04/10 15:39
Pinterest Technical Configuration: Is It a Short Squeeze or a Trap? Important Levels to Monitor
101 finance·2026/04/10 15:39
Flash
15:52
Circle minted 10.5 billion USDC on the Solana chain in the past monthChainCatcher reported, according to Lookonchain monitoring, Circle has just minted an additional 250 million USDC. Over the past month, Circle has minted 10.5 billion USDC on the Solana chain.
15:49
BlackRock withdraws 2,700 BTC and 30,000 ETH from a certain exchangeBlockBeats news, on April 10, according to Onchain Lens monitoring, BlackRock withdrew 2,700 BTC (worth 196.87 million USD) and 30,000 ETH (worth 67.42 million USD) from a certain exchange.
15:44
The U.S. Food and Drug Administration (FDA) stated in a complete response letter regarding Replimune Group Inc. that the current clinical data is insufficient to demonstrate significant efficacy of its oncolytic virus therapy, vusolimogene oderparepvec.Regulators believe that the currently submitted evidence does not meet the review standard of "substantial and effective proof," and require companies to provide additional clinical data to support the efficacy conclusions of this therapy.
News